Health experts have hailed major advances in dementia research for providing “real hope” to millions of patients around the world, but warned key hurdles must still be overcome to unlock the potential of promising treatments, reports BritPanorama.
The latest report on dementia – released to mark World Alzheimer’s Day on Monday – points towards a new era of care that could parallel the rapid developments observed in cancer treatment.
The Alzheimer’s disease International report indicates 158 potential therapies are currently under trial; however, several challenges could delay their arrival. “This is a moment of real hope for dementia research,” said Chris Lynch, acting chief executive of Alzheimer’s disease International.
“After decades of frustration, clinical trials have demonstrated for the first time that new treatments can slow the progression of Alzheimer’s disease, and a burgeoning pipeline of treatment trials brings real hope,” he added. The report also underscores that while advancements in biomarkers are promising, major barriers to recruiting trial participants could stifle progress.
Trial data
Active trials require around 55,000 participants, but a pool of approximately 350,000 is estimated to be necessary to meet regulatory and scientific requirements due to not all volunteers being suitable. Low awareness regarding the importance of dementia trials, limited GP referrals, travel costs, and strict eligibility criteria present considerable recruitment challenges that could hinder advancements.
“The advancement in blood-based biomarkers could revolutionise the way trials are recruited, drastically reducing screening costs and enabling recruitment on a scale that previously hasn’t existed,” stated Lynch. He emphasized the need for better referral pathways for clinical trials, as seen in oncology.
A notable challenge is that many dementia trials are conducted in high-income countries, such as the US, where a predominance of participants is white. This lack of diversity may undermine the scientific robustness of findings, as factors influencing dementia risk can vary across different populations.
Local researchers in the UAE are progressing with trials that aim to establish new benchmarks in dementia treatment for the Arab world. Under the Emirati Genome Programme, a million Emiratis have provided genetic data to expedite the development of new dementia drugs.
Africa, too, faces a pressing need for localized clinical dementia research. In regions like Kenya, the majority of the population dwells in rural areas, while clinical trials often occur in urban settings, which creates disparities in research access.
Care for all
Enhancing recruitment strategies in rural populations, alongside logistical support such as transportation to clinical trials, could significantly improve participation rates among underserved communities. Zul Merali, founding director of the Aga Khan University Brain & Mind Institute, noted that better targeting and support could lead to a substantial increase in the recruitment of appropriate populations.
In Cuba, a recent initiative by researchers collaborating with the Global Brain Health Institute trained local family doctors to recognize dementia symptoms, demonstrating a model that relies less on specialist infrastructure. Over a year, the study showed a rise in diagnosis rates, reinforcing the importance of early intervention.
Blood tests, along with symptoms like mild confusion or brain fog combined with family histories of dementia, are critical for prompting further investigations. Identifying risks may help patients slow disease progression and postpone severe symptoms.
Dr Derk Krieger, a neurological specialist at Fakeeh University Hospital, remarked, “We are witnessing a sea change in Alzheimer’s care.” He noted for the first time, emerging treatments could actually slow the underlying disease rather than merely alleviating symptoms.
“We need to reflect the patients we actually treat in our research,” he stressed, referencing the unique genetic and lifestyle characteristics of the Middle East. The UAE is preparing to open its first brain health clinic, aiming for proactive measures tailored to an ageing population.
Dr Krieger advocates for a more preventive approach to dementia care, similar to strategies used in cardiovascular health. “At age 40, you should start treating your blood pressure; for Alzheimer’s, it could take decades to develop,” he explained.
Brain clinics
The upcoming clinic targets individuals with family histories of dementia, those displaying symptoms, or those seeking health assessments. Addressing lifestyle factors, such as diet and exercise, is crucial for lowering the risk of neurodegenerative disorders.
National dementia plans are vital to establishing effective care pathways. Countries like Japan and South Korea have successfully integrated individuals living with dementia into community health strategies.
South Korea’s fifth national dementia plan, initiated in 2026, allows affected individuals to remain within their communities, while Japan’s long-term care insurance applies to everyone aged 65 and over and offers support based on formal diagnosis.
Dr Mohammad Ghatali, consultant neurologist at Mubadala Health Dubai, observed a shift towards preventive models in dementia care over the past five years. “We are moving from late intervention to earlier diagnosis,” he noted, highlighting the ongoing challenges of identifying Alzheimer’s prior to significant memory decline.
Recognizing changes early and connecting patients with appropriate care are essential objectives moving forward as the need for a proactive approach to brain health escalates.
